Publications by authors named "Irene Campana"

3 Publications

  • Page 1 of 1

Basal Cell Carcinoma: From Pathophysiology to Novel Therapeutic Approaches.

Biomedicines 2020 Oct 23;8(11). Epub 2020 Oct 23.

Istituto Dermopatico dell'Immacolata-IRCCS, via dei Monti di Creta 104, 00167 Rome, Italy.

Basal cell carcinoma (BCC) is the most common human cancer worldwide, and is a subtype of nonmelanoma skin cancer, characterized by a constantly increasing incidence due to an aging population and widespread sun exposure. Although the mortality from BCC is negligible, this tumor can be associated with significant morbidity and cost. This review presents a literature overview of BCC from pathophysiology to novel therapeutic approaches. Several histopathological BCC subtypes with different prognostic values have been described. Dermoscopy and, more recently, reflectance confocal microscopy have largely improved BCC diagnosis. Although surgery is the first-line treatment for localized BCC, other nonsurgical local treatment options are available. BCC pathogenesis depends on the interaction between environmental and genetic characteristics of the patient. Specifically, an aberrant activation of Hedgehog signaling pathway is implicated in its pathogenesis. Notably, Hedgehog signaling inhibitors, such as vismodegib and sonidegib, are successfully used as targeted treatment for advanced or metastatic BCC. Furthermore, the implementation of prevention measures has demonstrated to be useful in the patient management.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.3390/biomedicines8110449DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7690754PMC
October 2020

Neurothekeomas: Dermoscopic Features of 3 Cases.

Dermatol Pract Concept 2019 Oct 31;9(4):322-324. Epub 2019 Oct 31.

Dermatology Section, Department of Medical Science, Surgery and Neurological Sciences, University of Siena, Siena, Italy.

View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5826/dpc.0904a21DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830546PMC
October 2019

Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study.

Dermatol Ther 2016 Sep 5;29(5):372-376. Epub 2016 May 5.

Dermatology Department, Catholic University of the Sacred Heart, Rome, Italy.

Although the heterogeneity of the therapeutic response to TNF-α blockers seems to be mainly due to genetic factors, several studies showed that a range of factors may influence it. The aim of our study was to investigate the impact of patients' demographic and clinical characteristics on primary response to an anti-TNF-α therapy in psoriatic patients. We retrospectively examined the relationship between various clinical and demographic features and response to treatment with etanercept, adalimumab, and infliximab, evaluated as PASI75 and average PASI improvement at weeks 12, 16, and 14, respectively. We analyzed data obtained from 199 patients. A better response to the treatment was significantly associated with male gender (OR = 2.59), coexistence of psoriatic arthritis (OR = 1.97), and PASI ≤15 at baseline (OR = 0.91). The present study supports that some clinical factors may be potential predictors of response to anti-TNF-α agents in psoriatic patients.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.12364DOI Listing
September 2016
-->